Core Viewpoint - Kosen Technology announced that it received a regulatory letter from the Shanghai Stock Exchange regarding the sale of its wholly-owned subsidiary Kosen Medical's equity, highlighting concerns over the company's ongoing losses while the subsidiary reported revenue and profit [1] Financial Performance - Kosen Medical achieved revenues of 366 million yuan and 354 million yuan for the first three quarters of 2024 and 2025, respectively [1] - The net profits for Kosen Medical were reported at 41.12 million yuan and 47.24 million yuan for the same periods [1] - In contrast, the parent company continues to incur losses during this timeframe [1] Regulatory Requirements - The exchange has requested the company to provide additional disclosures, including the reasons for the losses and the financial impact of the transaction [1] - An independent board member's interviews and document reviews found no evidence of related party transactions or undisclosed interests in the deal [1] Internal Transactions - A special audit covering the period from 2018 to September 30, 2025, confirmed that transactions between Kosen Medical and the parent company, as well as its subsidiaries, were necessary, reasonably priced, and had commercial substance [1]

证券日报网讯12月12日，科森科技（603626）在互动平台回答投资者提问时表示，公司客户及合作情况 属于商业机密，未来任何重大业务拓展均会严格遵循公司决策程序，并及时履行信息披露义务。 ...

Group 1 - The company, Kosen Technology (603626.SH), confirmed that its products are exported overseas, including to Europe, the United States, and Southeast Asia [1] - The company expressed gratitude for investor interest regarding its export activities [1]

Core Viewpoint - Kosen Technology (603626.SH) announced the sale of its wholly-owned subsidiary, Kosen Medical, to Jiangsu Yaolingke Medical Technology Co., Ltd. for 915 million RMB, marking a significant strategic shift as the company exits the medical device sector [2] Group 1: Transaction Details - The transaction is based on an income approach, with the total equity value assessed at 913 million RMB as of September 30, 2025, reflecting an increase of 615 million RMB and a growth rate of 206.45% [2] - Kosen Technology expects to recognize approximately 600 million RMB in investment income from this divestiture, which will be recorded as non-recurring gains [2] - The deal is seen as a strategic acquisition for Yaolingke, enhancing its position in the precision medical device manufacturing sector [2] Group 2: Kosen Medical's Background - Kosen Medical has established itself as a competitive player in the medical device manufacturing industry, contributing to the high premium in the sale [7] - The company has collaborated with major clients like Medtronic, Zimmer, and Johnson & Johnson, providing critical components for various medical devices [9][10] - Despite its capabilities, Kosen Medical's revenue contribution has been low, accounting for about 10% of Kosen Technology's overall revenue, indicating its role as a supplementary business [6] Group 3: Reasons for Divestiture - Kosen Technology faced significant financial pressure, reporting cumulative losses of 873 million RMB from 2023 to the first three quarters of 2025, alongside high accounts receivable of 1.17 billion RMB [13] - The differing operational models between the consumer electronics and medical device sectors led to insufficient synergy, negatively impacting the efficiency of the core business [14] - The company aims to refocus on its core business in consumer electronics and energy storage, necessitating capital for overseas expansion projects [17] Group 4: Strategic Implications - The sale reflects broader challenges faced by manufacturing companies attempting to diversify into different sectors, particularly when operational demands and resource allocation become strained [26] - The entry of LYFE Capital into the medical manufacturing space signifies a shift towards asset acquisition in the global medical device sector, moving beyond previous focuses on R&D investments [27]

Core Viewpoint - Kosen Technology (603626.SH) is selling its wholly-owned subsidiary, Jiangsu Kosen Medical Devices Co., Ltd., for 915 million yuan to improve liquidity and focus on its core business after facing continuous losses in recent years [2][4][10] Group 1: Asset Sale Details - The sale involves transferring 100% equity of Kosen Medical to Jiangsu Yaoling Medical Technology Co., Ltd., a subsidiary of FSP Holdings Pte. Ltd., which is backed by LYFE Capital, a global investment platform in the healthcare sector [5][6] - The transaction is expected to increase Kosen Technology's investment income by approximately 600 million yuan in 2025, classified as non-recurring gains [4][6] Group 2: Financial Performance - Kosen Technology reported a cumulative loss of 873 million yuan attributable to shareholders from 2023 to the first nine months of 2025 [2][8] - As of September 2025, the company had total assets of 5.12 billion yuan and a debt-to-asset ratio of 58.34%, with accounts receivable amounting to 1.174 billion yuan [3][10] - In 2023 and 2024, the company experienced revenues of 2.597 billion yuan and 3.382 billion yuan, respectively, with net losses of 281 million yuan and 477 million yuan [8] Group 3: Business Focus and Strategy - Kosen Technology aims to exit the medical business to concentrate on its core operations in precision metal and plastic components for consumer electronics, while also exploring new sectors like energy storage [7][10] - The decision to divest from Kosen Medical is part of a broader strategy to optimize asset allocation and ensure sustainable business development [6][10]

Core Viewpoint - Kosen Technology announced the sale of its wholly-owned subsidiary, Kosen Medical, to Jiangsu Yaolingke Medical Technology Co., Ltd. for 915 million yuan, aiming to optimize its asset structure and focus on core business and emerging industries [2][3]. Group 1: Transaction Details - The transaction involves the sale of 100% equity of Kosen Medical, which was established in July 2018 with a registered capital of 118 million yuan, primarily engaged in the processing and export of minimally invasive surgical instruments [2]. - The buyer, Yaolingke, is a wholly-owned subsidiary of FSP, established specifically for this acquisition, with a registered capital of 64.55 million USD and a focus on medical device sales and technology import/export [3]. - The transaction price of 915 million yuan is based on an asset valuation report from Jinzheng (Shanghai) Asset Appraisal Co., Ltd., which estimated Kosen Medical's total equity at 913 million yuan, reflecting a 206.45% appreciation [4]. Group 2: Financial Performance of Kosen Medical - As of September 30, 2025, Kosen Medical reported total assets of 443 million yuan and net assets of 298 million yuan, with revenue of 354 million yuan and net profit of 47.24 million yuan for the first nine months of 2025 [3]. - For the fiscal year 2024, Kosen Medical's projected revenue is 366 million yuan, with a net profit of 41.12 million yuan [3]. Group 3: Transaction Conditions - Yaolingke is required to pay a 1 million USD earnest money within 10 working days after signing the agreement, which will be fully refunded later [4]. - The payment structure includes a 50% initial payment within 15 working days after meeting closing conditions, followed by the remaining 50% after completing business registration changes [4]. - Kosen Medical must maintain normal operations during the transition period and cannot undertake significant capital expenditures or asset disposals without written consent from Yaolingke [4].

Core Viewpoint - The company Kosen Technology (603626) plans to sell its 100% stake in Kosen Medical for 915 million RMB, marking a significant strategic shift as it exits the medical device sector and focuses on its core business in consumer electronics [1][3]. Group 1: Transaction Details - Kosen Technology will transfer its entire stake in Kosen Medical to Yaolingke for a consideration of 915 million RMB, reflecting a value increase of 206.45% [1]. - Following the transaction, Kosen Technology will no longer hold any equity in Kosen Medical, which will be excluded from the company's consolidated financial statements [3]. Group 2: Strategic Rationale - The sale aims to optimize asset allocation by divesting non-core businesses, allowing the company to concentrate on its main operations and emerging industries, thereby ensuring sustainable business development and improving performance [3]. - Kosen Medical, established in July 2018 with a registered capital of 118 million RMB, has faced challenges due to external market changes and ongoing US-China trade tensions, leading to limited synergy with Kosen Technology's core business [3]. Group 3: Financial Performance - Kosen Technology reported a revenue of 2.453 billion RMB for the first three quarters of 2025, a year-on-year decrease of 6.45%, with a net loss attributable to shareholders of 115 million RMB, although this represents a 50.94% improvement year-on-year [4]. - The company has been in a loss position for two consecutive years, with projected net losses of 281 million RMB and 477 million RMB for 2023 and 2024, respectively [4]. - Notably, Kosen Technology's overseas business has been growing rapidly, with foreign revenue reaching 2.109 billion RMB in 2024, a year-on-year increase of 26.45% [4].

Group 1 - Honghua Digital intends to acquire 49% equity of Shandong Yingkejie for 105 million yuan, resulting in full ownership of the company, which specializes in industrial inkjet technology [1] - Xue Ren Group's metal plate fuel cell stack project has passed final acceptance, delivering complete technical documentation and meeting performance requirements [2] - PIANO's controlling shareholder is planning a change in control, leading to a temporary suspension of its stock [3] Group 2 - COSCO SHIPPING Specialised Carriers plans to invest 258 million yuan in Shenshan Port Investment Company, acquiring a 20% stake [4] - Jieshun Technology has won a management project for an underground parking lot, expecting over 70 million yuan in revenue by the end of the contract in 2031 [5] - Aerospace Rainbow is collaborating with Zhongtian Rocket to establish a company focused on artificial weather modification technology with a total investment of 50 million yuan [6] Group 3 - Purun Co. intends to acquire 49% equity of Nuoya Changtian through a combination of shares, convertible bonds, and cash, making it a wholly-owned subsidiary [7] - Dongfang Yuhong plans to sell a commercial property for 10.12 million yuan, expecting a significant asset disposal loss [8] - Tianqi Lithium is applying for designated delivery warehouse qualifications for lithium hydroxide at the Guangzhou Futures Exchange [9] Group 4 - Tianfu Communication is planning to issue H-shares on the Hong Kong Stock Exchange, with details yet to be finalized [10] - ST Yishite's controlling shareholder will transfer 4.18 million shares to Hubei Jingjiang Industrial Investment Group, changing the actual controller to the Jingzhou State-owned Assets Supervision and Administration Commission [11] - Dongwei Technology's directors and key technical personnel plan to reduce their holdings by up to 1.11% of the company's shares [12] Group 5 - Guojin Securities shareholders plan to reduce their holdings by a total of 0.72% of the company's shares [23] - Hongde Co. controlling shareholder and associated parties plan to reduce their holdings by up to 3% [24] - Aopu Mai's restructuring plan to acquire 100% of Pengli Bio has been approved by the exchange [26] Group 6 - Kosen Technology intends to sell 100% of Kosen Medical for 915 million yuan due to challenges in its business environment [28] - Rongsheng Petrochemical's subsidiary plans to transfer 100% of Rongsheng Energy (Zhoushan) to Rongsheng Holdings [29] - Jingji Zhino reported a cumulative sales revenue of 3.464 billion yuan from pig sales in the first 11 months of 2025 [30]

Core Viewpoint - Kosen Medical, established in July 2018 with a registered capital of 118 million yuan, is facing challenges in its business development due to external market changes and ongoing Sino-U.S. trade tensions, with limited synergy with its core operations [1] Group 1: Company Overview - Kosen Medical primarily engages in the processing and export of minimally invasive surgical instruments [1] - The company will no longer be included in the consolidated financial statements following the completion of the transaction with Yaolingke, a wholly-owned subsidiary of FSP Holdings Pte. Ltd [1] Group 2: Transaction Details - The transaction is expected to increase the company's investment income by approximately 600 million yuan in the fiscal year 2025, aiding in cash flow recovery and reducing financial pressure [1] - Proceeds from the transaction will be used to supplement working capital, aiming to optimize the company's asset structure and fully exit the medical business [1] Group 3: Strategic Focus - Kosen Technology, the parent company, focuses on precision die-casting, forging, stamping, CNC, and laser cutting processes, providing precision structural components for well-known international clients such as Apple, Huawei, Amazon, and Google [1] - The strategic shift aims to further concentrate on the consumer electronics sector, enhancing operational levels and quality [1]

Group 1 - The company Kosen Technology (603626.SH) plans to sell its wholly-owned subsidiary Kosen Medical for 915 million yuan to Jiangsu Yaoling Medical Technology Co., Ltd [1][2] - Kosen Medical specializes in the processing and export of minimally invasive surgical instruments, but has faced challenges due to external market conditions and Sino-U.S. trade tensions [1][2] - The technology path and customer base of Kosen Medical differ significantly from the company's core business, resulting in limited synergy [1][2] Group 2 - The decision to sell the subsidiary is part of the company's strategy to optimize asset allocation and focus on its main business and emerging industries [1][2]